Cardiometabolic Benefits Beyond Weight Loss TRIUMPH-1 reported clinically meaningful improvements across multiple cardiometabolic risk markers alongside the weight loss data
Semaglutide (2.4mg, Wegovy): Approximately 14.9% body weight reduction over 68 weeks in the STEP trials
3094) was created in February 2024 and is about gastrointestinal complications (e.g., ileus, pancreatitis, and gastroparesis) that the drug allegedly caused
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Arcari D.P., Bartchewsky W., Jr., dos Santos T.W., Oliveira K.A., DeOliveira C.C., Gotardo E.M., Pedrazzoli J., Jr., Gambero A., Ferraz L.F., Carvalho Pde O., et al
The medication doesn't burn fat or magically make weight disappear
This targeted approach reduces the risk of hypoglycemia, a common concern with insulin therapy, allowing for safer diabetes management